After shining thanks to the councilor vaccines against COVVI-19, Pfizer intends to take market share in the obesity medication sector, a sector that expands today. The American laboratory will buy the Biotech Metsera for at least $ 4.9 billion, the two US companies announced on Monday, September 22 in a joint statement.
The operation, which must be completed in the fourth quarter of 2025, includes the redemption of Pfizer of Metsera shares for $ 47.5 per share, up to 4.9 billion dollars.
Lips to conquer the obesity and diabetes market
The success of the treatments against obesity and diabetes, a market currently dominated by the Danish Novo Nordisk, owner of Ozempic and Wogovy, and by the American Eliilly, owner of Zepbound, has exacerbated the appetite of the pharmaceutical companies that are acquired in the multiplied sector.
On Thursday, the Swiss Pharmaceutical Giant Roche, for example, bought the Californian company 89Bio, which specializes in liver and cardiometabolical diseases, for which it will pay almost $ 3.5 billion. In March 2025, the group also concluded an association with the Pharmaceutical of Zealand Danish to develop with you a treatment that acts on the hormone of satiety.
Pfizer had been one of the first laboratories in marketing a vaccine against messenger RNA against the COVVI-19, which had energized its income for several years. However, the course of action has decreased greatly since then, from more than $ 58 in December of 2021 to 24 dollars at the end of the New York Stock Exchange on Friday, September 19. In electronic bags before the opening of Wall Slet, the title of Pfizer won 1.6%, while Metsera flew 60% around 12:00 GMT.
Source: BFM TV
